The sizable discount and substantial dilution signal near-term selling pressure. Monitor for potential exercise of the underwriters' greenshoe option and any subsequent ATM sales. The extended cash runway reduces near-term financing risk but does not offset the dilutive overhang.
Price Chart
Executive Summary
Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, a ~8.8% discount to the prior close of $93.19. Net proceeds of ~$328.7M will fund pipeline advancement (gastroenterology, rheumatology, dermatology), Phase 3 readiness, and a new SPY072 late-stage HS program. The offering extends cash runway into 2H 2029 but causes immediate and substantial dilution of $71.51 per share for new investors.
Key Facts
- 4,117,648 shares offered at $85.00/share, raising ~$350M gross / ~$328.7M net
- Underwriters have a 30-day option for an additional 617,647 shares
- Public offering price represents an ~8.8% discount to the $93.19 prior close
- Immediate dilution of $71.51 per share for new investors (pro forma as-adjusted net tangible book value of $13.49 vs. $85.00 offering price)
- Proceeds extend cash runway into 2H 2029; company had ~$1.1B cash as of June 30, 2026
- Company and insiders subject to 60-day lock-up
- ~$451.6M remains available under the existing ATM facility
Financial Impact
~$329M net proceeds raised; immediate dilution of $71.51/share (84% of offering price); ~4.5% share count increase (4.1M new shares vs. ~88M pre-offering)
Risk Factors
- Immediate and substantial dilution of $71.51 per share for new investors
- Potential for further dilution from the greenshoe option, ATM facility, and future equity issuances
- Stock price may decline due to increased float and the discount to market
- No revenue or earnings data in filing to offset dilution concerns
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-065249 |
| Document: spyrefilingfees.htm | 0001628280-26-065249 |
| Document: 0001628280-26-065249-index-headers.html | 0001628280-26-065249 |
| Document: 0001628280-26-065249-index.html | 0001628280-26-065249 |
| Document: 0001628280-26-065249.txt | 0001628280-26-065249 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 9, 2026 18d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 7, 2026 20d ago | 8-K | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 6, 2026 21d ago | 424B5 | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | 424B5 | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 2, 2026 25d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $99.04 (−6.82%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $99.04 (−11.31%) |
Aug 10, 2026 11w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $99.04 (+3.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers